IGC Pharma (IGC) Retained Earnings (2011 - 2026)

IGC Pharma (IGC) has reported Retained Earnings for 16 consecutive years, with -$127.3 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Retained Earnings fell 5.42% year-over-year to -$127.3 million in Q1 2026; TTM through Mar 2026 was -$127.3 million, a 5.42% decrease from a year earlier, with the FY2026 full-year figure at -$127.3 million, down 5.42% from the prior year.
• Retained Earnings was -$127.3 million for Q1 2026 at IGC Pharma, down from -$124.9 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$89.2 million in Q1 2022 and troughed at -$127.3 million in Q1 2026.
• A 5-year average of -$110.4 million and a median of -$113.7 million in 2024 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings slipped 21.09% in 2022 and declined 4.3% in 2025, its largest moves.
• Over 5 years, Retained Earnings stood at -$96.6 million in 2022, then slipped by 14.64% to -$110.8 million in 2023, then retreated by 7.95% to -$119.6 million in 2024, then retreated by 4.43% to -$124.9 million in 2025, then declined by 1.92% to -$127.3 million in 2026.
• The last three Retained Earnings figures came in at -$127.3 million (Q1 2026), -$124.9 million (Q4 2025), and -$122.8 million (Q3 2025), per Business Quant data.